CALA - AVEO: A Speculative Buy
Here, I continue my coverage of the micro-cap oncology player AVEO Oncology (AVEO). In my previous piece, I discussed the issues AVEO encountered with the FDA regarding the results of the TIVO-1 trial, and how the FDA’s concerns may not be ameliorated by the available results of the TIVO-3 trial. On January 31, AVEO released a Press Release updating investors on delaying the timing of the potential NDA related to the TIVO-3 topline results. Here, I will outline the updated information AVEO has released in regard to correspondence with the FDA, including